title: DRESS syndrome with fatal results induced by sodium valproate in a patient with brucellosis and a positive cytoplasmic antineutrophilic cytoplasmic antibody test result.
abstract: DRESS syndrome is a life-threatening adverse reaction characterized by skin rashes, fever, leukocytosis with eosinophilia or atypical lymphocytosis, lymph node enlargement, and liver or renal dysfunctions. DRESS syndrome related to valproic acid use is very rarely observed. We present a case of DRESS syndrome induced by sodium valproate, which developed and progressed fatally in a brucellosis patient with a positive c-ANCA test. A 19-year-old female patient presented with fever, cough, jaundice, and rash all over her body. Brucella Coombs test was positive at 1:1280 titers, and the Rose Bengal test was also positive. The involuntary movements were thought to be due to chorea, and the patient was started on sodium valproate 500 mg 2 1, as well as streptomycin 1 g flk 1 1 and tetradox capsules 2 1 for the brucellosis and was discharged. DRESS syndrome was suspected in the patient, and she was taken off sodium valproate and tetradox; N-acetylcysteine, ceftriaxon, prednizolone, and support treatment were started. When sodium valproate is used on its own, it carries no risk of inducing DRESS syndrome. However, in the case presented, another co-morbidity such as brucellosis and c-ANCA positivity was present. We believe that the presence of further co morbidity not yet reported in literature is important from the perspective of the risk of valproate-induced DRESS syndrome. Therefore, if sodium valproate treatment is to be started in patients, especially those with co morbidity, they must be closely monitored with clinical and laboratory observations. At the slightest suspicion of DRESS syndrome, all medication should be ceased immediately and the patient should be placed under continuous observation.
authors.affiliation: Faculty of Medicine, Department of Internal Medicine, Ataturk University, Erzurum, Turkey. fatihalbayrakerz@gmail.com
authors.forename: Fatih
authors.initials: F
authors.lastname: Albayrak
authors.forename: Serkan
authors.initials: S
authors.lastname: Cerrah
authors.forename: Ayse
authors.initials: A
authors.lastname: Albayrak
authors.forename: Hakan
authors.initials: H
authors.lastname: Dursun
authors.forename: Rahsan
authors.initials: R
authors.lastname: Yildirim
authors.forename: Abdullah
authors.initials: A
authors.lastname: Uyanik
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000097:blood*; D000927:Anticonvulsants / Q000009:adverse effects*; D002006:Brucellosis / Q000188:drug therapy*; D003875:Drug Eruptions / Q000175:diagnosis*; D004802:Eosinophilia / Q000139:chemically induced*; D017809:Fatal Outcome; D005260:Female; D005334:Fever / Q000139:chemically induced; D006801:Humans; D013307:Streptomycin / Q000627:therapeutic use; D013577:Syndrome; D014635:Valproic Acid / Q000009:adverse effects*; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D019268:Antibodies, Antineutrophil Cytoplasmic; D000927:Anticonvulsants; D014635:Valproic Acid; D013307:Streptomycin